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Abstract: Systemic sclerosis (SSc) is a rare, multisystem disease
showing a large individual variability in disease progression and
prognosis. In the present study, we assess survival, causes of death,
and risk factors of mortality in a large series of Spanish SSc patients.
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hypertension (PH) was the leading cause in 23 (16.6%) patients.
Survival rates were 96%, 93%, 83%, and 73% at 5, 10, 20, and 30
years after the first symptom, respectively. Survival rates for diffuse
cutaneous SSc (dcSSc) and limited cutaneous SSc were 91%, 86%,
64%, and 39%; and 97%, 95%, 85%, and 81% at 5, 10, 20, and 30
years, respectively (log-rank: 67.63, P< 0.0001). The dcSSc subset,
male sex, age at disease onset older than 65 years, digital ulcers,
interstitial lung disease (ILD), PH, heart involvement, scleroderma
renal crisis (SRC), presence of antitopoisomerase I and absence of
anticentromere antibodies, and active capillaroscopic pattern showed
reduced survival rate. In a multivariate analysis, older age at disease
onset, dcSSc, ILD, PH, and SRC were independent risk factors for
mortality. In the present study involving a large cohort of SSc
patients, a high prevalence of disease-related causes of death was
demonstrated. Older age at disease onset, dcSSc, ILD, PH, and SRC
were identified as independent prognostic factors.
(Medicine 94(43):e1728)
Abbreviations: ACA = anticentromere antibodies, ACEI =
angiotensin-converting enzyme inhibitors, ACR = American
College of Rheumatology, ANA = antinuclear antibodies, ATA =
antitopoisomerase I antibodies, CI = confidence interval, CK =
creatine kinase, dcSSc = diffuse cutaneous systemic sclerosis,
DLCO = diffusing capacity of the lung for carbon monoxide,
EUSTAR = EULAR Scleroderma Trials and Research, FVC =
forced vital capacity, HR = hazard ratio, HRCT = high-resolution
CT Scan, IIF = indirect immunofluorescence, ILD = interstitial
lung disease, lcSSc = limited cutaneous systemic sclerosis, mRSS =
modified Rodnan skin score, PAH = pulmonary arterial
hypertension, PAP = pulmonary arterial pressure, PH =
pulmonary hypertension, pre-SSc = prescleroderma, RESCLE =
Registro de ESCLErodermia, RP = Raynaud phenomenon, RSHC =
right-sided heart catheterization, SD = standard deviation,
standardized mortality ratio, SRC = scleroderma renal crisis, SSc
= systemic sclerosis, SSSG = Spanish Scleroderma Study Group,
ssSSc = sine scleroderma systemic sclerosis.
INTRODUCTIONS ystemic sclerosis (SSc) is a rare, multisystem disease show-ing a large individual variability in the extent of skin and
organ involvement, as well as in disease progression and
www.md-journal.com | 1
(2)prognosis. Its natural course varies from a relatively benign
condition to a rapidly progressive disease, with a high risk of
mortality.1 Many studies have evaluated survival and predictors
of poor outcome in patients with SSc.2–8 However, this disease
is relatively uncommon, and results from small series of patients
may be nonrepresentative. In this sense, nationwide registers are
required to identify prognostic factors and the natural history of
SSc in real life.9–13 Large registries are important to define a
more uniform cohort of patients that allow recruiting patients
into clinical studies with comparable criteria for outcome
measurements. Up to now, only few multicentric studies exam-
ining survival in SSc patients have been reported with con-
siderable differences among them.3,14–16 Main explanations to
these controversies are differences on inclusion criteria and
differences on definition of clinical manifestations, survival
estimation from different time points (from disease onset or
from diagnosis of SSc), heterogeneity of disease course, and
different proportion of patients with diffuse and limited SSc
included in the series.
The extent of skin sclerosis has been considered an
important prognostic factor by several authors.5,17–25 In this
sense, SSc patients are usually subdivided into diffuse
cutaneous (dcSSc) and limited cutaneous (lcSSc) subsets
according to the most worldwide used classification proposed
by LeRoy et al.26 However, a third subset of patients named
SSc sine scleroderma (ssSSc) and defined by the presence of
Raynaud phenomenon (RP), any typical scleroderma visceral
involvement and positive antinuclear antibodies, but no
cutaneous sclerosis, was taken into account. This SSc subset
has not usually been considered in survival studies even
though different clinical characteristics between ssSSc and
lcSSc have been found by some authors.27,28 In our previous
study about clinical pattern according to cutaneous subsets and
immunological status of SSc patients, ssSSc subset was
already considered, and we detected a significant higher
prevalence of pulmonary and cardiac involvement in ssSSc
patients than in lcSSc subset.29
The importance of skin sclerosis and visceral involvement
as prognostic factors in SSc patients is not always concordant
among different studies.2–8,19–24 Moreover, survival hetero-
geneity was already evidenced by Pope30 in an Editorial that
included two meta-analyses about survival and mortality.31,32
Recently, causes and risk factors for death in SSc were also
reported by the The European League Against Rheumatism
(EULAR). In a multinational database by the EULAR Scler-
oderma Trials and Research (EUSTAR), 55% of deaths were
directly related to SSc, to lead by interstitial lung disease (ILD),
pulmonary arterial hypertension (PAH), and cardiac involve-
ment.25 The independent mortality risk factors in that series
were the presence of proteinuria on the urine dipstick analysis,
dyspnea on exertion, PAH, pulmonary restriction with lesser
than 80% of the predicted forced vital capacity (FVC), low
diffusing capacity of the lung for carbon monoxide (DLCO),
older age at onset of RP, and a modified Rodnan skin score
(mRSS) higher than 10. Intriguingly, SSc cutaneous subtype,
autoantibody status, and sex were not independent predictors of
subsequent death.
The present survey is a retrospective study of a cohort of
SSc patients enrolled in the first Spanish nationwide registry by
the Spanish Scleroderma Study Group (SSSG) or RESCLE
(Registro de ESCLErodermia as Spanish nomenclature) Reg-
Simeo´n-Aznar et alistry. The aim of this study was to analyze survival from disease
onset, causes of death, and risk factors associated with mortality
in a large series of SSc patients.
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Study Cohort
The SSSG or RESCLE was created by the Spanish Internal
Medicine Society in 2006, with the aim of compiling a large
series of Spanish patients with SSc. Fourteen Spanish centers
with experience in the management of these patients partici-
pated in the patient recruitment. All participating centers had
obtained ethics committee approval. To avoid excluding
patients with clear diagnosis who did not fulfill the American
College of Rheumatology (ACR) preliminary classification
criteria for SSc,33 we used a modification of the classification
proposed by LeRoy and Medsger.34 Thus, we considered ssSSc
patients as an independent subset of lcSSc to extend the
previously reported results from the same cohort of patients.29
Patients with SSc registered as deceased up to January 2008
were also analyzed. Epidemiological (including time and cause
of death), clinical, laboratory, capillarocopic, and immunologi-
cal data encompassing 90 variables were recorded according to
a standard protocol designed by the SSSG,5,6 and were entered
into a SPSS database. Disease onset was defined as the date of
the first self-reported symptom (RP in the majority of patients)
following the criteria of our previous study and in agreement
with other studies.1,5,6,15,16,25,35–41
Cutaneous Subsets
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Cohree groups of SSc patients were established according to
xtent of skin sclerosis, following a modification of the
34
the e
classification proposed by LeRoy and Medsger:
lcSSc, when the skin sclerosis was confined distally to the(1)
elbows and knees and/or the face,
dcSSc, when the skin thickening extended proximally to
the elbows and knees or included the trunk, and
ssSSc, defined by the presence of RP or a peripheral
vascular equivalent (digital pitting scars, fingertip ulcers,
SSc-type nailfold capillary pattern), scleroderma clinical(3)
features (gastrointestinal hypomotility, ILD, PAH, typical
cardiac involvement, or scleroderma renal crisis [SRC]),
and positive antinuclear antibodies, but no skin sclerosis.
Clinical Characteristics
‘‘Peripheral vascular manifestations’’ are defined by the
presence of RP, ischemic digital ulcerations, and acro-osteolysis
(tuft resorption secondary to digital ischemia identified in the
radiological study by radiologist). ‘‘Digestive tract involvement’’
considers any of the following diagnoses related to SSc: esopha-
geal involvement, when hypomotility of the lower two-thirds of
the esophagus and/or decreased peristalsis were confirmed by
manometry or cine-radiographic study; gastric involvement,
when gastric hypomotility was detected by radiographic or
radionuclide study, or when gastric antral vascular ectasia was
identified by endoscopy; intestinal involvement, when an intes-
tinal motility disturbance was confirmed by manometry or cine-
radiographic study, ormalabsorption syndromewas diagnosed by
breath test, or intestinal pseudo-obstruction was identified by
simple radiology or computerized tomography scan5,6; hepatic
involvement, when diagnoses of primary biliary cirrhosis, auto-
immune hepatitis, or nodular regenerative hyperplasia of the liver
were established. ‘‘Pulmonary involvement’’ is defined by the
presence of ILD or pulmonary hypertension (PH). ILD waslished if any of the following criteria were identified:
ctive pulmonary pattern with FVC below 80% of expected
on pulmonary function tests without other causes,
pyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
pulmonary interstitial pattern evidenced by chest radiograph or
high-resolution computed tomography (HRCT) scan, or alveolitis
confirmed by bronchoalveolar lavage (defined as neutrophilia of
3%, eosinophilia of 2%, or lymphocytosis 15%). PH was
considered when systolic pulmonary arterial pressure was esti-
mated to be above 40mm Hg by Doppler echocardiogram
corresponding to maximum tricuspid regurgitant jet velocity of
3.0m/s to 3.5m/s, or when mean pulmonary arterial pressure
(PAP)was found to be higher or equal to 25mmHgby right-sided
heart catheterization (RSHC).5,6 PHwas considered to be isolated
when ILD was not identified or was mild (FVC>70%). PH was
classified as ILD-associated if the patient had a restrictive
ventilator pattern with FVC <70% and severe lung fibrosis in
HRCT. ‘‘Muscle involvement’’ is defined by the presence of
proximal muscle weakness or myalgias and at least one of the
following abnormalities: serum creatine kinase (CK) over the
normal value or results of an electromyography (EMG)consistent
withmyopathy. ‘‘Joint and tendon involvement’’ is defined by the
presence of any of the following: arthralgia, arthritis, and tendon
friction rubs. ‘‘Heart involvement’’ was established by one or
more of the following: pericarditis, ischemic cardiomyopathy
with no known cause, reversible thallium perfusion defects after
cold stimulation,42 any disturbance on color-Doppler echocar-
diography, electrocardiographic alterations with no other cause,
left ventricular ejection fraction lower than 50% or right ven-
tricular ejection fraction lower than 40% on echocardiography or
radionuclide ventriculography. We assumed that ischemic cardi-
omyopathy was SSc-related only in the absence of other vascular
risk factors. ‘‘Scleroderma renal crisis’’ is defined by the presence
of a rapid deterioration of renal function (with concomitant
normal urine sediment) within a period of less than 1 month in
the absence of previous evidence of significant kidney disease or
by the combination of abrupt onset or aggravation of moderate to
severe arterial hypertension (>160/90mm Hg) accompanied by
manifestations of malignant hypertension (hypertensive grade III
or IV retinopathy, pulmonary edema, and/or hypertensive ence-
phalopathy) and elevation of peripheral renin activity to at least
twice the upper limit of normal as defined byTraub et al.43 ‘‘Sicca
syndrome’’ is defined as the presence of ocular and oral dryness,
and ocular signs and abnormal salivary gland function tests.
Nailfold Capillaroscopy
On the basis of the study by Maricq et al,44 2 main
capillaroscopic patterns were distinguished: an active pattern
characterized by predominant capillary loss, and a slow pattern
characterized by the presence of megacapillaries, but no signifi-
cant capillary loss.
Immunological Features
Antinuclear antibodies (ANAs) were identified by indirect
immunofluorescence (IIF) assay using Hep-2 cell lines or triple
tissue cryostat section (liver-stomach-kidney). Anticentromere
antibodies (ACAs), anti-Pm-Scl and antibodies to saline extrac-
table nuclear antigens (SSA/Ro, SSB/La, Sm, RNP, and topoi-
somerase I [ATA]) were determined.
Causes of Death
Causes of death of SSc patients were classified as SSc-
related mortality and unrelated to SSc. SSc-related deaths were
defined as deaths related to organ failure directly related to SSc:
pulmonary involvement (ILD, PH, or both); heart involvement
Medicine  Volume 94, Number 43, October 2015(ischemic cardiomyopathy, heart failure, or arrhythmias not
attributable to other cardiac conditions); renal involvement:
SRC and other SSc organ involvement. Unrelated to SSc were
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.all other causes not attributed to SSc organ involvement:
infection, cancer, cardiovascular disease, and other causes (a
variety of common causes of death not related to SSc).
Statistical Analysis
This study is a nationwide, retrospective analysis of SSc
subsets. Data about death were verified by 2 ways. Patients’ charts
were reviewed to determine the last follow-up. Patients were
classified as alive if they were followed up until January 2008.
For patients deceased in hospital, the cause of death was recorded
from charts. In the few cases in whom the date and cause of the
patient’s deathwere not available in the hospital’s medical records,
the informationwas frequently obtained from their relatives and/or
their General Practitioners. If there was no notification, the cause
of death was defined as ‘‘unknown.’’ Demographic features and
disease characteristics of alive and deceased patients at 2008 were
compared. Statistical evaluation was performed using a contin-
gency table test (chi-square test or Fisher exact test when necess-
ary) to identify significant differences. Kaplan–Meier methodwas
used to estimate survival from disease onset (RP in the majority of
patients), and Mantel–Haenszel statistic test (log-rank test) to
analyze differences in survival among subsets. Univariate com-
parison between groups was performed for all clinical character-
istics and immunological features. Variables that significantly
affected survival in the univariate analysis were entered into a
multivariate Cox proportional-hazards regression model with
both, forward and backward a stepwise selection procedure in
order to identify independent risk factors for mortality. Results
were consistent in forward and backward procedures. According
to a stepwise selection process, variables were entered, or
removed, from the regression equation on the basis of a computed
significance probability (maximized partial likelihood ratio) and
verified by a degree of hands-on modeling. The assumptions for
calculating the hazard ratio (HR) were checked byWald tests. All
statistical analyses were performed with SPSS 15.0 for Windows
(SPSS, Chicago, IL). The R project was employed for Kaplan–
Meier plots including number of patients in risk. A P value<0.05
was considered significant.
RESULTS
Scleroderma Subsets and Demographic Data of
Deceased Patients
By January 2008, 879 consecutive SSc Spanish patients
diagnosed according to the modified LeRoy and Medsger34
classification from 1970 were recruited on the SSSG database.
All patients were Caucasians. Demographic and clinical fea-
tures are shown in Table 1. Seven hundred forty-nine (85.2%)
were women. One hundred thirty-eight (15.7%) deaths were
registered overall and 112 (81.2%) of them were women. The
mean age at death was 64.1 13.2 years and the estimated mean
disease duration from disease onset to death was 7.2 10.7
years. Sixty-nine out of 138 (50%) deceased patients were
lcSSc, 63 (45.7%) were dcSSc, and 6 (4.3%) were ssSSc—
values significantly different with respect to alive patients at the
last follow-up (P< 0.0001). Patients who died were older at
disease onset and at SSc diagnosis (47.7 15.2 vs 44.4 15.8,
and 54.7 14.1 vs 50.6 15.1, respectively).
Clinical and Immunological Features in Deceased
Survival in Systemic Sclerosisand Alive Patients
Organ involvement and scleroderma manifestations of
deceased and alive patients at the assessment time were
www.md-journal.com | 3
ABLE 1. ComparisonofDemographic,Clinical, and Immuno-
gical Features of Deceased and Survivor Systemic Sclerosis
atients
Deceased,
n (%)
Survivors,
n (%) P
umber of
patients
138 (15.7) 741 (84.3)
SSc 69 (50.0) 498 (67.2) <0.0001
cSSc 63 (45.7) 180 (24.3) <0.0001
sSSc 6 (4.3) 63 (8.5) <0.0001
emale 112 (81.1) 637 (86.0) 0.025
ge at disease
onset
47.7 15.2 44.4 15.8 0.868
ge at diagnosis 54.7 14.1 50.6 15.1 0.626
Sc duration 7.2 10.7 6.1 8.5 0.004
igital ulcers 79 (57.2) 300 (40.5) <0.0001
elangiectasies 97 (70.3) 434 (58.7) 0.011
alcinosis 41 (29.7) 126 (17.0) 0.001
rthritis 36 (26.8) 113 (15.3) 0.001
endon friction
rubs
11 (3.1) 14 (8.1) 0.010
crosteolysis 30 (21.7) 51 (7.1) <0.0001
igestive
involvement
113 (82.0) 500 (67.6) <0.0001
Esophagus 90 (65.2) 416 (56.2) 0.029
Barret esophagus 10 (7.2) 16 (2.2) 0.004
Malabsortion 8 (5.8) 14 (2.0) 0.014
D 99 (71.7) 322 (43.5) <0.0001
H 58 (42.0) 103 (14.0) <0.0001
earth involvement 89 (64.5) 201 (27.0) <0.0001
Ischemia 28 (20.3) 64 (8.6) <0.0001
Conduction
alteration
42 (30.4) 60 (8.0) <0.0001
RC 15 (11.0) 9 (1.2) <0.0001
ancer 15 (11.0) 32 (4.3) <0.0001
CA negative
(n¼ 808)
74 (66.0) 378 (51.0) 0.024
ACA¼ anticentromere antibodies, dcSSc¼ diffuse cutaneous systemic
clerosis, ILD¼ interstitial lung disease, lcSSc¼ limited cutaneous
ystemic sclerosis, PH¼ pulmonary hypertension, SCR¼ scleroderma
meo´n-Aznar et alT
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Sicompared and results are shown in Table 1. In brief, dcSSc,
digital ulcers, acro-osteolysis, and organ involvements were
more prevalent in patients who died. The cancer incidence in
deceased patients was significantly higher than in alive patients.
Among the malignancies, breast cancer (15 among 47 malig-
nancies) and lung cancer (9 among 47 malignancies) were
clearly most prevalent. The remaining malignancies were dis-
tributed as follow: 6 hematologic neoplasm, 5 skin cancer, 4
colon, 3 tiroides, 3 disseminated malignancies of unknown
origin, 2 kidney, 2 corpus uteri, and 1 prostate.
Causes of Death
Seventy-six out of 138 (55%) deceased patients diedbecause
nal crisis, ssSSc¼ systemic sclerosis sine scleroderma. Continuous data
are presented as meanSEM.of causes directly attributed to SSc, and pulmonary involvement
was the main cause. Isolated PH was the most frequent SSc-
related cause of death, present in 23 (16.6%) patients, followed by
4 | www.md-journal.comILD in 18 (13.0%) and PH related to ILD in 17 (12.3%). SRCwas
a rare cause of death recognized in 12 (8.7%) patients. Sixty-two
out of 138 (45%) deceased patients died because of non-SSc–
related causes. Cancer was the leading cause in 16 (11.6%)
patients, followed by heart failure (not attributable to SSc) in
12 (8.7%) patients. Among the malignancies, lung (4) and breast
cancer (3) were most prevalent. When we take into account SSc
subtype, the main cause of death was PH in lcSSc patients (17
[24.7%]), ILD in dcSSc patients (13 [20%]), and PH related to
ILD in ssSSc patients (2 [33.3%]). The majority of deaths related
to SRC occurred in patients with dcSSc. All data are shown in
Table 2.
Survival Rates
Overall, mean survival time was 46.4 4.2 years (95%
confidence interval [CI] 38–54) and survival rates were 96%,
93%, 83%, and 73% at 5, 10, 20, and 30 years after the first
symptom, respectively. Survival rates for the 3 SSc cutaneous
subtypes are shown in Figure 1. Survival rates for lcSSc and
ssSSc patients were 96%, 94%, 83%, and 74%; and 98%, 98%,
86%, and 86% at 5, 10, 20, and 30 years, respectively. No
statistical differences were found between both groups
(P¼ 0.755). Survival rates for dcSSc patients were worse than
the other subsets—91%, 86%, 64%, and 39% at 5, 10, 20, and 30
years, respectively. Once confirmed that survival rates were
similar for lcSSc and ssSSc subsets, both groups were combined
in order to compare survival rates of the new largest group
(97%, 95%, 85%, and 81% at 5, 10, 20, and 30 years, respect-
ively) with those of the dcSSc subset. The survival rate of the
combined group was significantly better than the dcSSc subset
(log-rank 67.63, P< 0.0001).
The Kaplan–Meier survival curves according to the pre-
sence or absence of clinical and immunological features were
significantly different on log-rank test, as shown in Figure 2.
Pairs of survival curves with significant differences and the
survival rates of subgroups at 10, 20, and 30 years after the onset
of SSc are shown in Figure 2 and Table 3. Subgroup analysis
revealed that the presence of lung, heart, and kidney involve-
ment was associated with worse prognosis.
Of note, dcSSc, male sex, age at first symptom older than
65 years, digital ulcers, ILD, PH, heart involvement, SRC,
presence of ATA and absence of ACA, and active capillaro-
scopic pattern showed significant differences in survival.
Prognostic Factors
Univariate analysis of all significant parameters (log-rank
test) related to mortality showed that dcSSc, male sex, age at
first symptom older than 65 years, digital ulcers, ILD, PH, heart
involvement, SRC, presence of ATA, and absence of ACAwere
all associated with diminished survival (Table 4). When multi-
variate analysis using Cox proportional-hazard model (HR) was
performed, older age at disease onset, dcSSc, and the presence
of ILD, PH, and/or SRC were confirmed to be independent risk
factors for mortality (Table 5).
DISCUSSION
In the present study involving 879 Spanish SSc patients, a
high prevalence of disease-related causes of death was demon-
strated, and dcSSc, older age at disease onset, ILD, PH, and
Medicine  Volume 94, Number 43, October 2015SRC were identified as independent prognostic factors for
mortality. The prevalence of SSc mortality-related causes in
our study is similar to those identified in previous registries and
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Causes of Death in 138 Spanish Systemic Sclerosis Patients
Causes, n (%) lcSSc 69 (50.0) dcSSc 63 (45.7) ssSSc 6 (4.3) Total SSc 138
SSc-related 76 (55.0)
PH 17 (24.7) 5 (8.0) 1 (16.0) 23 (16.6)
PH þ ILD 6 (8.6) 9 (14.3) 2 (33.3) 17 (12.3)
ILD 5 (7.2) 13 (20.0) 0 (0) 18 (13.0)
SRC 3 (4.3) 9 (14.3) 0 (0) 12 (8.7)
Ischemic cardiopathy 0 (0) 1 (1.6) 2 (33.3) 3 (2.1)
PBC 3 (4.3) 0 (0) 0 (0) 3 (2.1)
Non-SSc–related 44 (31.8)
Cancer 8 (11.5) 7 (11.1) 1 (16.0) 16 (11.6)
Heart failure 8 (11.5) 4 (6.3) 0 (0) 12 (8.7)
Septicemia 2 (3.0) 1 (1.6) 0 (0) 3 (2.1)
Other causes 5 (7.5) 8 (12.7) 0 (0) 13 (9.4)
Unknown causes 12 (17.0) 6 (9.5) 0 (0) 18 (13.0)
isea
s, s
Medicine  Volume 94, Number 43, October 2015 Survival in Systemic Sclerosismeta-analyses.8,25,31,32,36 Thus, pulmonary involvement (ILD
and/or PH) was the leading cause of death in agreement with
previous observations.8,14,25 Classically, PH has been con-
sidered the main cause of death in patients with lcSSc, but
not in patients with dcSSc. However, recent studies showed that
this pulmonary vascular complication is a frequent clinical
manifestation in all SSc subsets29,39,45 and leads to death in
many dcSSc patients as well. In the present cohort, 5 and 9
dcSSc patients (22.2%) died because of isolated PH and PH
related to ILD, respectively. Since the introduction of the
angiotensin-converting enzyme inhibitors (ACEIs), SRC has
become a less frequent terminal event in patients with SSc.8,46
In the present cohort, SRC accounted for 8.7% of all deaths
dcSSc¼ diffuse cutaneous systemic sclerosis, ILD¼ interstitial lung d
cirrhosis, PH¼ pulmonary hypertension, SRC¼ scleroderma renal crisidespite the ACEI treatment. This is a slightly higher incidence
than that observed in the Pittsburgh and EUSTAR cohorts,8,25
but similar to the reported incidence by the recent meta-
FIGURE 1. Kaplan–Meier survival curves for systemic sclerosis
(SSc) patients from disease onset according to cutaneous subsets
of SSc.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.analysis.31,32 Our data underline that renal involvement plays
an important role in SSc mortality yet, and indicates that further
efforts are needed to improve management of this complication.
Among non-SSc–related causes of death, malignancies
and cardiovascular involvement, in particular, heart failure,
were the most frequently identified. In accordance with our
results, several studies have suggested an increased incidence of
cancer in patients with SSc.45,47,48 Specifically, in the Medi-
terranean area, Airo´ et al49 in a retrospective evaluation of 360
Italian patients with SSc observed a history of malignancies in
10.8% of the patients; in the present study, the prevalence was
lower (5.3%), but direct comparison is not possible because of
different patient selection and different objective. The malig-
nancies were already identified as a major cause of death in
several studies.2,14,25,31,36,37
To discriminate SSc from non-SSc–related heart involve-
ment in older patients is sometimes challenging and then we
assumed that ischemic cardiomyopathy was SSc-related only in
the absence of other vascular risk factors.
In the present cohort, survival rates of SSc patients were
better than those described in other studies.31,39,45,50–54 Differ-
ences may be attributed to methodological and clinical reasons.
Firstly, survival was estimated from the first clinical manifes-
tation of SSc, usually RP, according to Domsic and Medsger1
recommendations. They stated that RP is the first symptom in
the majority of lcSSc patients and in 40% of dcSSc patients.
Moreover, the first non-RP symptom occurs at a mean of 5
months after the first symptom attributable to SSc in dcSSc
patients.1 In agreement with this statement, currently, the
majority of studies considered RP as the first manifestation
of SSc.15,16,38–40,55 Secondly, we used a modified LeRoy et al34
classification that allowed recruiting patients with milder
clinical SSc variants and reflected the whole spectrum of
SSc. It is known that survival of SSc patients has improved
over time,5,7,8,31,33,45,50–54,56 and older studies usually included
a relatively higher percentage of patients with more severe
disease. Indeed, in the cohort from Ferri et al; the 10-year
survival rate of patients included before 1985 was worse than
se, lcSSc¼ limited cutaneous systemic sclerosis, PBC¼ primary biliary
sSSc¼ systemic sclerosis sine scleroderma.that of the patients included beyond (60.6% vs 76.8%;
P< 0.0001).3 Probably, this finding is related to the systematic
annual screening of the organ-based complications and the
www.md-journal.com | 5
FIGURE 2. Kaplan–Meier survival curves of patients with systemic sclerosis according to (A) age at disease onset, (B) sex, (C) digital ulcers,
(D) interstitial lung disease, (E) pulmonary hypertension, (F) heart involvement, (G) scleroderma renal crisis, (H) capilaroscopic pattern, (I)
antitopoisomerase I, and (J) anticentromere antibodies.
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TABLE 3. Comparison Between Groups From Log-rank (Mantel Cox) and 5, 10, and 20-Year Survival Rates, Estimated by the
Kaplan–Meier Method of Spanish Systemic Sclerosis Patients According to Demographic, Clinical, and Immunological Variables
(Crude Analysis)
Survival (95% CI)

Log-rank (Mantel-Cox) P 5-year 10-year 20-year
Cutaneous subset
(dcSSc vs lcSSc þ ssSSc)
67.620 <0.0001 91 (88–95) 86 (81–91) 64 (55–73)
Sex (male vs female) 8.705 0.003 90 (84–96) 85 (78–92) 69 (58–92)
Age at disease onset
(>–65 vs <65 yrs)
50.952 <0.0001 91 (85–97) 81 (71–91) 49 (28–69)
Digital ulcers (yes vs no) 6.703 0.010 95 (92–98) 92 (88–95) 80 (73–88)
Heart involvement
(yes vs no)
36.383 <0.0001 93 (90–96) 88 (84–92) 73 (67–79)
ILD (yes vs no) 39.605 <0.0001 94 (92–97) 90 (87–93) 75 (69–80)
PH (yes vs no) 44.167 <0.0001 95 (91–98) 87 (81–93) 66 (57–76)
Capillaroscopic pattern
(slow vs active)
4.391 0.036 93 (90–97) 90 (85–94) 81 (73–88)
SRC (yes vs no) 55.232 <0.0001 56 (35–76) 49 (28–71) 29 (7–51)
ATA (positive vs negative) 8.539 0.003 94 (90–98) 90 (85–95) 76 (67–85)
ACA (negative vs positive) 8.996 0.003 94 (92–97) 92 (89–95) 79 (74–85)
ACA¼ anticentromere antibodies, ATA¼ antitopoisomerase I antibodies, CI¼ confidence interval, dcSSc¼ diffuse cutaneous systemic sclerosis,
CR
Medicine  Volume 94, Number 43, October 2015 Survival in Systemic Sclerosisimprovement of the current organ therapies. Eighty-five percent
of patients in our study were diagnosed beyond 1990 and it may
explain the high survival rates we identified. Thus, Ferri et al57
recently reported an interesting study underlining the evolution
of SSc pathomorfosis and prognosis during the time. The
authors reviewed the world literature and observed increased
median 10-year survival from 54% (patients recruited in 1955–
1985) to 83.5% (patients recruited between 1999 and 2011). The
authors observed that the worse prognostic factors were less
ILD¼ interstitial lung disease, PH¼ pulmonary arterial hypertension, S
Survival rates for subgroup in bold.frequent in recently recruited Italian series. Thus, the prevalence
of dcSSc, ATA, digital ulcers, and main visceral organ involve-
ment was less commonly detected. In Ferri et al’s recent cohort
TABLE 4. Risk Factors for Reduced Survival in Systemic
Sclerosis Patients by Cox Univariate Analysis
Risk Factor HR HR (95% CI) P
dcSSc 4.046 (2.793–5.862) <0.0001
Male 1.882 (1.215–2.915) 0.005
Age at disease
onset 65
11.063 (5.961–20.532) <0.0001
Digital ulcers 1.518 (1.066–2.160) 0.020
ILD 3.229 (2.190–4.761) <0.0001
PH 3.211 (2.259–4.566) <0.0001
Heart involvement 3.421 (2.335–5.012 <0.0001
SRC 5.921 (3.412–10.275) <0.0001
ATA positive 1.820 (1.180–2.807) 0.007
ACA negative 1.773 (1.189–2.644) 0.005
ACA¼ anticentromere antibodies, ATA¼ antitopoisomerase I anti-
bodies, CI¼ confidence interval, dcSSc¼ diffuse cutaneous systemic
sclerosis, HR¼ hazard ratio, ILD¼ interstitial lung disease, PH¼
pulmonary hypertension, SCR¼ scleroderma renal crisis.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.(patients recruited between 2000 and 2011), the cumulative
10th-year survival rate calculated from RP was 95.4%, which is
similar to that in the present study (93%).
In our study, survival rates of dcSSc patients were higher
compared with those found in some cohorts,39,45,54 but our
results are in accordance with recent Japanese15 and
Norwegian56 studies.
The present study included a large number of variables
potentially influencing survival of SSc patients such as sex, age
at disease onset, cutaneous subsets, visceral involvement, and
the presence or absence of ACA and ATA. We evaluated the
independent predictor factors in terms of HR, and lung involve-
ment (ILD and/or PH), dcSSc, SRC, and age at disease onset
¼ scleroderma renal crisis.older than 65 years were identified as independent factors of
lesser survival rate. Although older age at disease onset was
found an independent risk factor in many studies,2,3,5,6,14,18,36
TABLE 5. Independent Risk Factors for Reduced Survival of
Systemic Sclerosis Patients by Cox Multivariate Regression
Modeling
Risk Factor HR Lower Upper P
SRC 6.448 2.887 14.400 <0.0001
ILD 3.187 1.517 6.694 0.002
dcSSc 2.700 1.656 4.401 <0.0001
PH 2.690 1.734 4.172 <0.0001
Age at disease
onset
 1.115 1.079 1.153 <0.0001
dcSSc¼ diffuse cutaneous systemic sclerosis, HR¼ hazard ratio,
ILD¼ interstitial lung disease, PH¼ pulmonary arterial hypertension,
SCR¼ scleroderma renal crisis.
As continuous variable.
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results should be adjusted according to the matched general
population because survival rate usually decreases with aging.
Accordingly, Pe´rez-Bocanegra et al50 used standardized
mortality ratio (SMR) analysis and concluded that older age
at disease onset of SSc had worse survival rate than younger age
at disease onset, even though they had lcSSc, which is known as
the best prognostic subset. However, when SMRwas adjusted to
the expected background population mortality rates, mortality
was only slightly increased in the subset older than 65 years
(SMR 1.2). Hoffman-Vold et al56 observed SMR of 2.03.
It is known that dcSSc patients have worse outcome than
lcSSc2,5,14,15,35–37,39,46,51,56 because of its predisposition to
develop internal organ involvement.29,30,32 Specifically, lung
and renal involvements are more prevalent and severe in the
former and may explain the highest mortality evidenced in
dcSSc patients. Thus, multivariate analysis identified SRC as a
major risk factor for death (HR 6.448) with a low survival rate at
5 years despite an early ACEI therapy in the acute SRC
phase.5,6,16,32
Interstitial lung disease was the second risk factor for
death, with a HR of 3.187. Pulmonary restriction has been
described as an independent risk factor in previous stu-
dies.8,25,32,56 In our study, ILD was a leading cause of death
in 25.3%, and it was related to PH in 12.3% of them. Therefore,
the development of PH in patients with ILD is associated to
worse prognosis.
In this study, PH represented an important independent risk
factor of mortality and it was the main cause of death, either
isolated (16.6%) or related to ILD (12.3%), in agreement with
Hachulla et al,14 who observed that PAH was a major risk factor
for death with a HR of 7.246 during a 3-year period. These
observations underline the increasing impact of pulmonary
vascular complication on SSc survival.14,30–32
Other factors such as male sex, heart involvement, pre-
sence of ATA, and absence of ACA were associated with poor
prognosis in the univariate analysis and the survival study.
However, we could not demonstrate they were independent
risk factors. These results are similar to the EUSTAR study and
the Spanish cohort.25,39
The main strengths of the present study are the recruitment
of a large cohort of SScpatients from14hospitals in Spain and the
long-term follow-up period, given the relative low prevalence, as
well as the homogeneous demographic composition of the
sample, because only patients of Spanish origin were included.
Nevertheless, some limitations are recognized such as the retro-
spective design of the survey and the fact that the cause of death
was unknown in 18 patients, which represented 13% of deaths.
This percentage is similar to that described in a recent meta-
analysis (16%)31 and in the EUSTAR prospective study (4%).25
The SMR was not estimated in the mortality study.
Despite these limitations, we believe that our study
represents a real picture of the Spanish SSc patient evolution.
Taken together, our data demonstrated a high prevalence of
disease-related causes of death being lung involvement. Inde-
pendent risk factors for mortality were dcSSc, age at the most
frequent disease onset, ILD, PH, and SRC. Therefore, improve-
ment on SSc patients’ prognosis is related to advances of
therapy for lung involvement.
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